Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with si...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2004-10, Vol.94 (8), p.1047-1050
Main Authors: Rha, Seung-Woon, Kuchulakanti, Pramod K., Pakala, Rajbabu, Cheneau, Edouard, Fournadjiev, Jana A., Pinnow, Ellen, GebreEyesus, Afework, Aggrey, George, Wang, Zuyue, Pichard, Augusto D., Satler, Lowell F., Kent, Kenneth M., Lindsay, Joseph, Waksman, Ron
Format: Article
Language:English
Subjects:
Anticoagulants - therapeutic use
Cardiology
Drug Carriers - adverse effects
Drug therapy
Female
Heparin - therapeutic use
Hirudins - analogs & derivatives
Humans
Male
Middle Aged
Peptide Fragments - therapeutic use
Recombinant Proteins - therapeutic use
Retrospective Studies
Sirolimus - administration & dosage
Stents
Stents - adverse effects
Thrombosis - etiology
Thrombosis - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2004.06.065